ATE146968T1 - Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie - Google Patents
Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapieInfo
- Publication number
- ATE146968T1 ATE146968T1 AT90104450T AT90104450T ATE146968T1 AT E146968 T1 ATE146968 T1 AT E146968T1 AT 90104450 T AT90104450 T AT 90104450T AT 90104450 T AT90104450 T AT 90104450T AT E146968 T1 ATE146968 T1 AT E146968T1
- Authority
- AT
- Austria
- Prior art keywords
- functional derivatives
- adhesion molecule
- intercellular adhesion
- molecule icam
- antivirus
- Prior art date
Links
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title abstract 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title abstract 2
- 230000002155 anti-virotic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32407389A | 1989-03-16 | 1989-03-16 | |
| US45429289A | 1989-12-22 | 1989-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE146968T1 true ATE146968T1 (de) | 1997-01-15 |
Family
ID=26984265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90104450T ATE146968T1 (de) | 1989-03-16 | 1990-03-08 | Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie |
| AT96107522T ATE219838T1 (de) | 1989-03-16 | 1990-03-08 | Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96107522T ATE219838T1 (de) | 1989-03-16 | 1990-03-08 | Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP0391088B1 (de) |
| JP (1) | JP3166854B2 (de) |
| KR (1) | KR0178024B1 (de) |
| AT (2) | ATE146968T1 (de) |
| AU (1) | AU648016B2 (de) |
| CA (1) | CA2012125C (de) |
| DE (2) | DE69029528T2 (de) |
| DK (2) | DK0745852T3 (de) |
| ES (2) | ES2097748T3 (de) |
| GR (1) | GR3022846T3 (de) |
| HK (1) | HK1003104A1 (de) |
| HU (1) | HU220235B (de) |
| NZ (1) | NZ232920A (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514936B1 (en) | 1988-09-01 | 2003-02-04 | Bayer Corporation | Antiviral methods using human rhinovirus receptor (ICAM-1) |
| ES2141076T3 (es) | 1988-09-01 | 2000-03-16 | Bayer Ag | Proteina del receptor de rinovirus humano que inhibe la infectividad del virus. |
| US6051231A (en) * | 1988-09-01 | 2000-04-18 | Bayer Corporation | Antiviral methods and prepations |
| US6143298A (en) * | 1988-09-01 | 2000-11-07 | Bayer Corporation | Soluble truncated forms of ICAM-1 |
| ZA896668B (en) * | 1988-09-01 | 1990-06-27 | Molecular Therapeutics Inc | A human rhinovirus receptor protein that inhibits virus infectivity |
| US5776775A (en) * | 1989-02-21 | 1998-07-07 | Dana-Farber Cancer Institute | Anti-LAM 1-3 antibody and hybridoma |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| DK0387668T3 (da) * | 1989-03-09 | 1997-03-03 | Blood Res Center | Intercellulært adhæsionsmolekyle-2 og dets bindende ligander |
| WO1991018010A1 (en) * | 1990-05-15 | 1991-11-28 | Swinburne Limited | Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof |
| US5674982A (en) * | 1990-07-20 | 1997-10-07 | Bayer Corporation | Multimeric form of human rhinovirus receptor protein |
| US6107461A (en) * | 1990-07-20 | 2000-08-22 | Bayer Corporation | Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use |
| US5871733A (en) * | 1990-07-20 | 1999-02-16 | Bayer Corporation | Multimeric forms of human rhinovirus receptor protein |
| DE69131564T2 (de) * | 1990-07-20 | 2000-01-13 | Bayer Ag | Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins |
| EP0510483A1 (de) * | 1991-04-22 | 1992-10-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Verfahren zum Nachweis von Viren |
| EP0650367A4 (de) * | 1992-06-01 | 1998-04-15 | New England Medical Center Inc | Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen. |
| DE4335273A1 (de) * | 1993-10-15 | 1995-04-20 | Univ Ludwigs Albert | Peptide zur Tumortherapie |
| WO1995027736A1 (en) * | 1994-04-12 | 1995-10-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection |
| AU698406B2 (en) * | 1994-04-19 | 1998-10-29 | University Of Kansas, The | ICAM-1/LFA-1 short-chain peptides and method of using same |
| AU1122697A (en) * | 1995-11-22 | 1997-06-11 | Research And Development Institute, Inc. | Therapeutic and diagnostic agents for the treatment of microbial infections |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| WO1997032596A1 (en) * | 1996-03-06 | 1997-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Intercellular adhesion molecule powder formulation |
| US6075004A (en) * | 1996-04-26 | 2000-06-13 | The University Of Kansas | Peptide compositions which induce immune tolerance and methods of use |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| AU777241B2 (en) | 1999-06-24 | 2004-10-07 | Johns Hopkins University, The | Compositions and methods for preventing transepithelial transmission of HIV |
| GB0216729D0 (en) * | 2002-07-18 | 2002-08-28 | Glaxo Group Ltd | Animal models |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289949B1 (de) * | 1987-05-04 | 1995-10-04 | Dana Farber Cancer Institute | Interzellulare Adhäsions-Moleküle und deren Bindungsliganden |
| CA1341055C (en) * | 1987-12-08 | 2000-07-18 | Alan Mcclelland | Transfectant cell lines which express the major human rhinovirus receptor |
| ES2141076T3 (es) * | 1988-09-01 | 2000-03-16 | Bayer Ag | Proteina del receptor de rinovirus humano que inhibe la infectividad del virus. |
| WO1990003400A1 (en) * | 1988-09-28 | 1990-04-05 | Dana-Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
| NO900155L (no) * | 1989-01-24 | 1990-07-25 | Molecular Therapeutics Inc | Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1. |
-
1990
- 1990-03-08 DE DE69029528T patent/DE69029528T2/de not_active Expired - Lifetime
- 1990-03-08 EP EP90104450A patent/EP0391088B1/de not_active Expired - Lifetime
- 1990-03-08 ES ES90104450T patent/ES2097748T3/es not_active Expired - Lifetime
- 1990-03-08 ES ES96107522T patent/ES2177695T3/es not_active Expired - Lifetime
- 1990-03-08 DK DK96107522T patent/DK0745852T3/da active
- 1990-03-08 AT AT90104450T patent/ATE146968T1/de not_active IP Right Cessation
- 1990-03-08 DE DE69033983T patent/DE69033983T2/de not_active Expired - Lifetime
- 1990-03-08 EP EP96107522A patent/EP0745852B1/de not_active Expired - Lifetime
- 1990-03-08 AT AT96107522T patent/ATE219838T1/de not_active IP Right Cessation
- 1990-03-08 DK DK90104450.3T patent/DK0391088T3/da active
- 1990-03-14 HU HU585/90A patent/HU220235B/hu unknown
- 1990-03-14 CA CA002012125A patent/CA2012125C/en not_active Expired - Lifetime
- 1990-03-14 NZ NZ232920A patent/NZ232920A/en unknown
- 1990-03-15 KR KR1019900003454A patent/KR0178024B1/ko not_active IP Right Cessation
- 1990-03-15 AU AU51294/90A patent/AU648016B2/en not_active Expired
- 1990-03-15 JP JP06549590A patent/JP3166854B2/ja not_active Expired - Lifetime
-
1997
- 1997-03-17 GR GR970400521T patent/GR3022846T3/el unknown
-
1998
- 1998-03-16 HK HK98102150A patent/HK1003104A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1003104A1 (en) | 1998-10-09 |
| HU220235B (hu) | 2001-11-28 |
| DE69033983T2 (de) | 2003-03-20 |
| AU5129490A (en) | 1990-09-20 |
| CA2012125A1 (en) | 1990-09-16 |
| ES2177695T3 (es) | 2002-12-16 |
| CA2012125C (en) | 2003-07-29 |
| ATE219838T1 (de) | 2002-07-15 |
| HUT56133A (en) | 1991-07-29 |
| EP0745852A1 (de) | 1996-12-04 |
| DE69033983D1 (de) | 2002-08-01 |
| EP0391088B1 (de) | 1997-01-02 |
| JPH0372430A (ja) | 1991-03-27 |
| EP0391088A3 (de) | 1991-10-02 |
| GR3022846T3 (en) | 1997-06-30 |
| KR0178024B1 (ko) | 1999-03-20 |
| JP3166854B2 (ja) | 2001-05-14 |
| EP0745852B1 (de) | 2002-06-26 |
| KR900013984A (ko) | 1990-10-22 |
| DK0745852T3 (da) | 2002-10-14 |
| HU901585D0 (en) | 1990-06-28 |
| DE69029528D1 (de) | 1997-02-13 |
| DE69029528T2 (de) | 1997-06-26 |
| AU648016B2 (en) | 1994-04-14 |
| EP0391088A2 (de) | 1990-10-10 |
| ES2097748T3 (es) | 1997-04-16 |
| NZ232920A (en) | 1997-05-26 |
| DK0391088T3 (da) | 1997-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69033983T2 (de) | Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie | |
| DE69008664D1 (de) | Bestrahlung von bluterzeugnissen. | |
| DE3781240D1 (de) | Vorrichtung zur stimulation von gliedversteifungen. | |
| DE3854700D1 (de) | Verwendung von wässrigen kationischen Kunststoffdispersionen zum Imprägnieren und Grundieren von saugfähigen Substraten. | |
| GR3006073T3 (de) | ||
| FI875544A0 (fi) | Anvaendning av 3'-deoxitymidin-2'-en (3'-deoxi-2',3'-didehydrotymidin) foer behandling av patienter infekterade med retrovirus. | |
| DE3751576D1 (de) | Virale Inaktivierung und Reinigung von aktiven Proteinen. | |
| BR8707096A (pt) | Projetil comportando subprojeteis com zona de eficacia predefinida | |
| DE3767550D1 (de) | Oberflaechenbehandlung von titangegenstaenden. | |
| DE3885913D1 (de) | Aufbereitung von Alkoxysilanen. | |
| DE68910320D1 (de) | Behandlung von holz und auf holz basierenden stoffen. | |
| DE3675654D1 (de) | Nach amplitude ausgeglichenes und anpassbarer laser. | |
| DE3767175D1 (de) | Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen. | |
| ATE143058T1 (de) | Typisierung humaner rhinoviren | |
| DE3777022D1 (de) | Verfahren und praeparat zur inaktivierung von viren. | |
| DE3863093D1 (de) | Sulfosuccinamidsaeuren von polyoxypropylendiaminen und ihre verwendung als emulgatoren. | |
| DE3769332D1 (de) | Derivate von pyrido-menadion-additionsprodukten und verwendungen davon. | |
| DE3886765D1 (de) | Derivate von synergimycinen a und b. | |
| DE69002234D1 (de) | Ultraschallbehandlung von teigerzeugnissen. | |
| ATE74755T1 (de) | Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. | |
| DE69430188T2 (de) | Behandlung von hiv-infektionen mittels huminsäure | |
| ATE81454T1 (de) | Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen. | |
| DE3788424D1 (de) | Testverfahren des menschlichen b-lymphotropen virus (hblv). | |
| NO873102L (no) | Modifiserte virale glykoproteiner, samt diagnostiske og terapeutiske anvendelser derav. | |
| ATE62678T1 (de) | Derivate von pyrido-menadion-additionsprodukten und verwendungen davon. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties | ||
| EEWE | Authorization for restitution | ||
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |